TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02022761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate
Description: 40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate
Description: 40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Laninamivir octanoate
Description: 40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
Study: NCT00964041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg by mouth weekly, one hour before assessments, for eight weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
Study: NCT01250184

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Twelve sessions (3 per week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection
Description: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine injection + physical therapy
Description: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
Study: NCT04654611

Intervention type: DRUG
Group type: OTHER
Intervention: preservative free tafluprost 0.0015%
Description: preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
Study: NCT03091517

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GlycoLeap
Description: GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback.
Study: NCT03639636

Intervention type: OTHER
Group type: OTHER
Intervention: non surgical and surgical periodontal therapy
Description: scaling and root planing periodontal flap surgery
Study: NCT02604602

Intervention type: OTHER
Intervention: blood exam
Description: laboratory test

Intervention type: OTHER
Intervention: blood exam
Description: laboratory test
Study: NCT04277663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310+IBI308
Description: In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Description: In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose recombinant interferon a-2B
Description: In this group, subjects will be given 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
Study: NCT01904474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Next.Step - e-therapeutic intervention program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment protocol
Study: NCT01922947

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motivational Interviewing w/Social Network Counseling
Description: This is the active arm of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Condition
Description: 20-minute health counseling
Study: NCT02138409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray (FSS)
Description: Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray (FSS)
Description: Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray (FSS)
Description: Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sublingual Spray (PSS)
Description: Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sublingual Spray (PSS)
Description: Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
Study: NCT01880294

Intervention type: DRUG
Intervention: No intervention
Description: Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
Study: NCT01581034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PADMA 28
Description: PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
Study: NCT01891799

Intervention type: OTHER
Intervention: Option B+
Description: * Using one low toxicity triple ARV regimen \[(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)\] for all women, rather than adapting regimens by CD4+~* Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART~* Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women
Study: NCT01271712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: 160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily (od), 3 weeks on/1 week off. Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
Study: NCT01059682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Description: Dalcetrapib 600 mg orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally once daily
Study: NCT02580123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention taught by trained educators
Study: NCT01407835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control
Description: Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Study: NCT03086291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days
Study: NCT04446624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy intervention
Description: Group psychotherapy with music intervention
Study: NCT02018848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Program
Study: NCT04793724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simeox
Description: A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~* clearance of the upper airways before the physiotherapy session~* correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~* slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~* step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~* comfortable, relaxed sitting position with straightened spine~* controlled cough, which will be encouraged only when it is productive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PARI O PEP
Description: ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~* horizontal;~* low;~* transition of the device from the low position to the horizontal position;~* upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum.
Study: NCT02339142

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: 100 Rads to each lateral orbit x 10 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous corticosteroids (methylprednisolone)
Description: Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous corticosteroids (methylprednisolone)
Description: Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
Study: NCT00675623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon, 5 mg orally three times daily for six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon 20 mg orally three times daily for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times daily for six months
Study: NCT04361409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 on Day-14 and Day-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70mg/m2 on Day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 on Day8
Study: NCT04652206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCO-101
Description: Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Used according to marketing authorisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Used according to marketing authorisation
Study: NCT02446249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1
Description: Infusion of gene therapy
Study: NCT03110978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy
Study: NCT01733862

Intervention type: OTHER
Intervention: Data collection
Description: Data sheet. Data will be collected and is planned to be analysed at the following time points:~Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016.
Study: NCT03192280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukotriene B4
Description: Leukotriene B4 (LTB4)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLIR One
Description: Thermal imaging attachment to iPhone
Study: NCT01918683

Intervention type: RADIATION
Group type: OTHER
Intervention: TACE transarterial chemoembolization

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TACE transarterial chemoembolization

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotatic body radiotherapy (SBRT)
Study: NCT03489824

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified- WIM colonoscopy
Description: Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified- WIM colonoscopy
Description: Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
Study: NCT03580694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4659
Description: REGN4659 will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered by intravenous (IV) infusion.
Study: NCT03859349

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Selective Targeted Sampling
Description: After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Sampling
Description: Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
Study: NCT00450684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation and testing of CRT
Description: Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation and testing of CRT
Description: Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation and testing of CRT
Description: Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation and testing of CRT
Description: Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
Study: NCT03519646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat
Description: 1. This is a 3-year study and the enrollment time of this study is 24 months.~2. The participants have to receive the investigational agent, Cerdelga~3. The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~4. IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~5. No need for fasting before use, but can't take with grapefruit juice.~6. Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test.
Study: NCT01310101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab plus dexamethasone
Description: Dose and schedule~Cycle 1:~Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18~Cycles 2 to 6 (cycles every 28 days):~Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18
Study: NCT04581161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Life2000® Ventilator
Description: POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded.
Study: NCT03657511

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Interventions to Promote Tobacco Cessation
Description: Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks.
Study: NCT01918930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGA271
Description: MGA271 anti-B7-H3 monoclonal antibody
Study: NCT03630952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mg Conbercept Intravitreal Injection
Description: Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1.0 mg Conbercept Intravitreal Injection
Description: Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2.0 mg Aflibercept Intravitreal Injection
Description: Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
Study: NCT03748147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: prostaglandin e1
Study: NCT03192280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCIO
Description: Handheld near-IR molecular spectroscopy device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MS Band 2
Description: Wearable watch-like device with multiple sensors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGE reader
Description: Portable bench top device for in-clinic near UV assessment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HSI prototype (PARC) hyper-spectral camera
Description: Portable bench top device for in-clinic multispectral imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPhone 7
Description: Smart phone
Study: NCT04451226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral
Study: NCT03748147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: prostaglandin e1